Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome (SBS), although its share price remains under pressure.
Interim results of the VIBRANT study of vurolenatide have identified a suitable dosing regimen for the drug to take forward into phase 3, with preliminary evidence of efficacy and a favourable safety profile, said the North Carolina biotech.
